ArticleEuropean journal of medical research2026
Machine learning-based prognostic model for local control prediction in lung cancer patients undergoing stereotactic body radiation therapy: a preliminary study.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposePredicting local recurrence after stereotactic body radiation therapy (SBRT) for lung cancer remains challenging. This study aims to develop a machine learning (ML)-based prognostic model for local control (LC) prediction by comparing different ML algorithms.
methodsClinical data from 158 lung cancer patients treated with SBRT were retrospectively analyzed. Six ML methods, including Boruta, RSF, GBM, LASSO, CoxBoost, and univariate Cox regression were systematically applied to perform variables selection, and the final prognostic model was constructed using multivariate Cox regression analysis. A benchmark model incorporating clinical stage plus treatment dose was also used for comparison. The performance of different models was evaluated using the C-index, Akaike Information Criterion (AIC), and time-dependent AUC. The optimal model was further evaluated comprehensively through receiver operating characteristic (ROC) analysis, calibration plots assessment, and decision curve analysis (DCA). The evaluation was validated through internal cross-validation to ensure robust reliability.
resultsThe LASSO-Cox model achieved the highest C-index (0.718) and time-dependent AUC, shared the lowest AIC with the CoxBoost-Cox model, and outperformed the conventional stage plus treatment dose model (0.718 vs. 0.634). The LASSO-Cox model demonstrated moderate discriminatory ability, good calibration (predicted vs. observed outcomes), and clinical utility in DCA.
conclusionsML demonstrates certain potential in LC prediction after SBRT. Nevertheless, it is worth noting that the study relies solely on internal validation and lacks external validation; therefore, further validation in independent cohorts is required before the model can be responsibly considered for clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.